| Website | vpgenetics.com |
| Category | BioTech |
| Employees |
| Series A, 11/09 Mohr Davidow Ventures X/Seed Capital | $6M |
VitaPath Genetics is developing a family of DNA tests to help individuals reduce the risk of serious and life-threatening disease. Their first product is a genetic test to identify risk factors that are associated with a common birth defect called Spina Bifida and which can be safely corrected with low-risk vitamin supplementation under the care of a physician.
